Under the agreement, Emerald and ChemDiv will use their transitional and integrated drug discovery and development platform to support collaborative efforts.
ChemDiv Biology CTO and vice president Ilya Okun said ChemDiv and Emerald capabilities complement each other and bring together a combination of technologies to improve drug discovery and development efforts.
"This collaboration demonstrates the commitment of both companies to further improve customer experiences," Okun said.